City University of New York (CUNY)

CUNY Academic Works
Student Theses

John Jay College of Criminal Justice

Spring 6-2019

Method Development and Validation for the Determination of
Designer Benzodiazepines in Blood by LC-MS/MS
Victoria Mei
CUNY John Jay College, vickytoria.mei@gmail.com

How does access to this work benefit you? Let us know!
More information about this work at: https://academicworks.cuny.edu/jj_etds/102
Discover additional works at: https://academicworks.cuny.edu
This work is made publicly available by the City University of New York (CUNY).
Contact: AcademicWorks@cuny.edu

Method Development and Validation for the Determination of Designer Benzodiazepines in
Blood by LC-MS/MS

A Thesis Presented in Partial Fulfillment of the Requirements for the Degree of
Master of Science in Forensic Science
John Jay College of Criminal Justice
The City University of New York

Victoria Mei
May 2019

Method Development and Validation for the Determination of Designer Benzodiazepines in
Blood by LC-MS/MS

Victoria Mei

This thesis has been presented to and accepted by the office of Graduate Studies, John Jay
College of Criminal Justice in partial fulfillment of the requirements for the degree of Master of
Science in Forensic Science.

Thesis Committee:
Thesis Advisor: Dr. Marta Concheiro-Guisan
Second Reader: Dr. Gail Cooper
Third Reader: Dr. Madeleine Swortwood

Table of Contents

Pages

Acknowledgments

i

Abstract

ii

Keywords

iii

List of Tables

iv

List of Figures

v

1. Introduction

1

2. Materials and Methods

3

2.1 Reagents and Supplies

3

2.2 Preparation of Calibrators and QCs

4

2.3 Sample Extraction

6

2.4 Instrumental Parameters

6

2.5 Method Validation

9

2.6 Identification Criteria

12

2.7 Authentic Sample Analysis

13

3. Results

13

3.1 Chromatography

13

3.2 Method Validation

14

3.3 Case Sample Analysis

23

4. Discussion

25

5. Conclusion

28

6. Future Work

28

7. References

28

8. Appendix
Appendix A: Acronyms and Abbreviations

33
33

Appendix B: Extracted ion chromatograms of each analyte at 3 ng/mL 34

i

Acknowledgements
I would like to express my sincerest gratitude to my advisor, Dr. Marta Concheiro, for
providing endless patience and guidance towards my research. This project would not be where
it is today without all her help in filling the gaps for parts I did not understand. I would also like
to sincerely thank Dr. Gail Cooper for the opportunity to conduct such an interesting thesis
research at the New York City Office of Chief Medical Examiner and working in a laboratory
environment that increased my learning experience. I would like to thank all the professional
forensic toxicology staff that helped me adapt to the laboratory environment, answered questions
I may have, and came to my aid when troubleshooting problems. I am extremely and eternally
grateful and would like to give a special thank you to Justine Pardi, who was always there for me
throughout the entire process of this research project despite having school and case work and
teaching me all she could regarding the liquid chromatography-mass spectrometer until I was
comfortable enough to work independently. I would also like to thank Dr. Madeleine Swortwood
for being my third reader and setting time to review my work.
Lastly, I would like to express the utmost gratitude to my family, boyfriend, and friends
for their never ending support, patience, and continuous encouragement throughout my years of
study, research process, and writing this thesis. This accomplishment would not have been
completed without all the help I have received. Thank you all so much.

ii

Abstract
The misuse of

designer benzodiazepines, as

an alternative

to

prescription

benzodiazepines and for drug-facilitated sexual assaults, has emerged as a growing threat, due in
part to the ease of purchasing these drugs on the internet at low prices. Causing concern for
safety, is the lack of dosage information resulting in users self-medicating, often leading to
unintended overdoses, coma, or death at higher doses. With limited published data regarding
quantification of designer benzodiazepines in forensic cases, a method was validated for the
determination of thirteen and screening for two designer benzodiazepines in blood, in addition to
a limited number of common designer benzodiazepines in the inhouse method. The developed
method

analyzed

3-hydroxyphenazepam,

4-chlorodiazepam,

clobazam,

clonazolam,

delorazepam, deschloroetizolam, diclazepam, flualprazolam, flubromazepam, flubromazolam,
flunitrazolam, meclonazepam, nifoxipam, pyrazolam, and zolazepam in 0.5 mL blood using
liquid chromatography-tandem mass spectrometry. The analytes were treated with solid phase
extraction before undergoing separation on a 𝐶18 column and analyzed on the mass spectrometer
in electrospray positive mode using multiple-reaction monitoring. The linear range of the
calibration curve was 1-200 ng/mL, and up to 500 ng/mL for 3-hydroxyphenazepam, clobazam,
flubromazepam, and pyrazolam. 4-chlorodiazepam and zolazepam were tested for qualitative
analysis only. The limits of detection and quantitation were 0.5 ng/mL (S/N>3) and 1 ng/mL,
respectively. Other parameters tested included bias, precision, matrix effect, recovery, carryover,
stability, interference, and dilution integrity which all yielded acceptable results. With the
application of this method to blood specimens from the NYC Office of Chief Medical Examiner,
this validated method proved to be simple, reproducible, sensitive, and robust.

iii
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1. Introduction
Benzodiazepines are drugs that are usually prescribed to treat various kinds of medical
conditions including but not limited to anxiety, seizures, insomnia, and depression. However,
benzodiazepines also come with several side effects, such as confusion, memory loss, loss of
orientation, headaches, and have the potential of being addictive (Ogbru, 2018). Due to their
psychoactive effects and side effects, benzodiazepines have been employed in drug-facilitated
sexual assaults; they may produce driving impairment, and even death from overdoses in
combination with other central nervous system depressants, such as ethanol and opioids (NIH
National Institute on Drug Abuse, 2019; Vikingsson et al., 2017). In addition to benzodiazepines,
currently gaining traction for substance abuse are designer benzodiazepines because they are
easily accessible, can be bought online, are cheap, and most do not fall under the Controlled
Substance Act, with the exception of clobazam and delorazepam, at the time of publication, so
they are unmonitored (Moosmann, King, & Auwarter, 2015).
Designer benzodiazepines, which fall under new psychoactive substances (NPS), such as
etizolam, diclazepam, flubromazolam, clobazam, and nifoxipam, are even more potent and
dangerous than regular benzodiazepines, so the same dosage can produce the same or even
greater effect on the body (Moosmann et al., 2015). For instance, studies show that clonazolam is
2.5 times more potent than alprazolam with a 20-60 minutes onset of action. Clonazolam causes
sedation, muscle relaxation, amnesia, respiratory depression, and withdrawals leading to anxiety
or seizures can occur if the user stops taking it immediately without tapering (Cornett et al.,
2018). For flubromazepam, one of the authors, who self-administered 4 mg of the drug as a
capsule, felt fatigue and the need to sleep for three days (Moosmann et al., 2013). Because they
are treated as research chemicals sold online, users do not always know specific dosages, but
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rather self-assess how much of the drug to take. This can often result in unintentional
overdosing, which can potentially lead to coma or death, especially if combined with other
depressant substances.
With the introduction of designer benzodiazepines in the market, there is a lack of
standardized methods in the toxicology laboratories to screen for the presence of these drugs and
to confirm these findings in biological samples. Immunochemical tests and enzyme linked
immunosorbent assays can be used for a preliminary screening; but the target of these screening
tests are the classic benzodiazepines, and the cross reactivity with the new designer
benzodiazepines is unknown. Gas chromatography-mass spectrometry (GC-MS) has also been
used as a screening technique that includes the use of library matches with good sensitivity and
selectivity, however there can be false negative results for drugs that undergo thermal
decomposition. In addition, GC-MS analysis is not as sensitive to metabolites and co-eluting
chromatographic peaks (Guale et al., 2013). Currently, there are several methods described that
screen a limited number of designer benzodiazepines, including clonazolam, deschloroetizolam,
flubromazepam, flubromazolam, and meclonazepam, using liquid chromatography time-of-flight
mass spectrometry (LC-TOF/MS) and liquid chromatography quadrupole time-of-flight mass
spectrometry (LC-QTOF/MS). However, these methods utilized urine and serum as the matrix of
analysis and the sample clean-up procedure consisted of liquid-liquid extraction (LLE) or solid
phase extraction (SPE) (Guale et al., 2013; Huppertz, Bisel, Westphal, & Franz, 2015;
Moosmann et al., 2013; Pope, Choy, Drummer, & Schneider, 2018; Tomková, Švidrnoch, Maier,
& Ondra, 2017).
There are also limited methods available to confirm and quantify the presence of these
new compounds (American Association for Clinical Chemistry, 2018). There are methods
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developed to determine the presence of designer benzodiazepines by gas chromatography with
tandem mass spectrometry (GC-MS/MS) (Nakamae et al., 2008; Meng, Zhu, Zheng, & Fu, 2017)
and by liquid chromatography with tandem mass spectrometry (LC-MS/MS) in urine or plasma
as the matrix (Bergstrand, Helander, & Beck, 2016; Oliveira-Silva et al., 2009), but few for antemortem and post-mortem blood and are limited in the number of designer benzodiazepines tested
(Sauve, Langodegard, Ekeberg, & Oiestad, 2012). Blood is a critical matrix in forensic
toxicology because blood concentrations can be correlated with impairment. Thus, the purpose of
the study was to develop and validate a method for the confirmation and quantification of 15
designer benzodiazepines in blood by LC-MS/MS.

2. Materials and Methods
2.1. Reagents and Supplies
3-Hydroxyphenazepam (1 mg/mL in acetonitrile), clobazam (1 mg/mL in methanol),
clonazolam (1 mg/mL in acetonitrile), delorazepam (100 µg/mL in acetonitrile),
deschloroetizolam (1 mg/mL in methanol), diclazepam (1 mg/mL in acetonitrile),
flubromazepam (1 mg/mL in methanol), flubromazolam (1 mg/mL in methanol), meclonazepam
(1 mg/mL in methanol), nifoxipam (1 mg/mL in 90:10 acetonitrile: dimethyl sulfoxide, v/v),
pyrazolam (1 mg/mL in acetonitrile), zolazepam (1 mg/mL in methanol), 7-aminoclonazepam-𝑑4
(1 mg/mL in acetonitrile), diazepam-𝑑5 (1 mg/mL in methanol), chlordiazepoxide-𝑑5 (100
µg/mL in methanol), nordiazepam-𝑑5 (1 mg/mL in methanol), and temazepam-𝑑5 (1 mg/mL in
methanol) were purchased from Cerilliant (Round Rock, TX). Flualprazolam and flunitrazolam
were purchased as powder from Cayman Chemicals (Ann Arbor, MI). 4-chlorodiazepam was
purchased as powder from Sigma-Aldrich (St. Louis, MO). Ethyl acetate and ammonium
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hydroxide were purchased from Sigma-Aldrich (St. Louis, MO). LCMS grade acetonitrile,
formic acid, and deionized water were purchased from Spectrum (New Brunswick, NJ).
Drug-free (negative) calf blood was obtained from Ottomanelli Bros. (New York, NY)
for the preparation of calibrators and quality control (QC) samples. Postmortem blood samples
obtained from the New York City Office of Chief Medical Examiner (NYC-OCME) were from
expired cases previously tested for the presence of common prescription benzodiazepines and a
limited number of designer benzodiazepines (desalkylflurazepam, etizolam, nimetazepam, and
phenazepam) were used to determine matrix effects.
Preconditioned Clean Screen XCEL I SPE columns (130 mg/6 mL) were purchased from
United Chemical Technologies (Levittown, PA). The SPE columns were mounted on a SPEware
CEREX® System 48 Processor positive pressure manifold (Tecan, Männedorf, Switzerland).

2.2. Preparation of Calibrators and QCs
Prior to preparing a working solution, the powders of 4-chlorodiazepam, flualprazolam,
and flunitrazolam were individually dissolved in methanol to a final concentration of 1 mg/mL.
Then, a working solution of a mixture of all fifteen designer benzodiazepines was prepared in
methanol at 10 mg/L. Additional working solutions at 1 mg/L and 0.1 mg/L were prepared
through serial dilution of the 10 mg/L working solution in methanol. Two sets of working
solutions were prepared, one for calibrators and one for QC samples. A working standard of a
mixture all five internal standards (IS) was prepared at a concentration of 1 mg/L in methanol.
All solutions were mixed and stored at -20°C when not in use.
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Calibration standards were prepared by adding the appropriate volumes of the working
solutions of analytes to 0.5 mL negative calf blood, that was aliquoted into labeled 16 x 125 mm
glass culture tubes, to final concentrations of 1, 5, 10, 50, 100, 200, and 500 ng/mL. QC samples
were prepared using the same method as the calibrators to final concentrations of 3, 40, 80, and
300 ng/mL. The volumes of the appropriate stock solution for each desired concentration is
shown below in Table 1.

Table 1. Guidelines for the Spiking of Calibrators and quality control (QC) Samples
Sample Type
Calibrator

QC

Final Concentration
(ng/mL)

Stock Solution of
Calibrator or QC (mg/L)

Volume Added
(µL)

1

0.1

5

5

0.1

25

10

0.1

50

50

1

25

100

1

50

200

10

10

500

10

25

3

0.1

15

40

1

20

80

1

40

300

10

15
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2.3.Sample Extraction
To 0.5 mL aliquots of all the blood samples, including calibrators, QC samples, and case
sample blood, 50 µL of the IS working solution (1 mg/L) was added, resulting in a final
concentration of 100 ng/mL, and vortexed using the Scientific Industries Vortex Genie Z
(Scientific Industries Inc, Bohemia, NY). One mL of acetate buffer (pH 4.5) was added to each
tube and mixed by vortexing for 30 s. The tubes were centrifuged at 3,000 rpm for 10 min using
the Beckman Coulter Allegra X-15R Centrifuge (Beckman Coulter, Brea, CA). The centrifuged
samples were decanted onto the SPE cartridges with applied pressure at 1-2 psi. After, the
column was washed with 3 mL of distilled water and 3 mL of 5% acetonitrile in acetate buffer
(pH 4.5) with applied pressure at 2-4 psi. The columns were dried for 15 min at 60 psi. The
analytes were eluted with 2 mL of ethyl acetate: ammonium hydroxide (98:2, v/v). Lastly, the
eluate was evaporated to dryness under nitrogen at 40℃ with the SPEware CEREX® 48
Concentrator (Tecan, Männedorf, Switzerland), reconstituted with 0.1 mL of the initial mobile
phase, vortexed for 3 s, centrifuged at 3,000 rpm for 10 min and transferred to sample vials with
polymer feet for LC-MS/MS analysis.

2.4.Instrumental Parameters
Two Agilent 1200 Infinity Series LC Systems equipped with an autosampler combined
with an Agilent 6460 Triple Quadrupole mass spectrometer (Agilent Technologies, Santa Clara,
CA) were used for the duration of the analysis. An Agilent InfinityLab Poroshell 120 EC18
column (3.0 mm x 50 mm, 2.7 μm particle size) held at a temperature of 55°C in the column
compartment was used for chromatographic separations. The mobile phase consisted of 0.1%
formic acid in water (solvent A) and 0.1% formic acid in acetonitrile (solvent B) at a flow rate of
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0.7 mL/min. The starting gradient conditions were 15% B, which increased to 20% B over 1.5
min, then increased to 32% B by 10 min, and lastly ramped to 100% B by 10 min, holding it for
2 min. The system was then equilibrated back to initial conditions for 1.5 min, with a total run
time of 13.5 min. The mass spectrometer (MS) analyzed the compounds using Agilent jet
stream-electrospray ionization (AJS-ESI) under positive mode and data were collected using
multiple reaction monitoring (MRM). The MS parameters included a gas temperature of 300°C,
gas flow at 6 L/min, nebulizer at 40 psi, and capillary voltage at 4 kV. All data was recorded and
processed using Agilent MassHunter Quantitative Analysis for QQQ (B.07.01 SP2). The MS
parameters for each compound was determined using the Agilent MassHunter Optimizer
program. The two most abundant product ions of MRM transitions were chosen for each analyte,
the first for quantitation and the second for ion ratio comparison as confirmation as shown in
Table 2.

Table 2. MRM Parameters for the 15 Designer Benzodiazepines and 5 internal standards. The
quantifier ions are the transitions highlighted in bold.
Compound Name

Retention
Time (min)

Precursor
Ion (m/z)

Product Ion Fragmentor
(m/z)
(V)

3-hydroxyphenazepam

7.9

365

318.9

120

21

346.9

120

13

227

165

33

154

165

29

259

150

17

224.1

150

33

308

175

28

280

175

40

4-chlorodiazepam

Clobazam

Clonazolam

11.1

9.1

6.3

319

301.1

354

Collision
Energy (V)

8
Delorazepam

Deschloroetizolam

Diclazepam

Flualprazolam

Flubromazepam

Flubromazolam

Flunitrazolam

Meclonazepam

Nifoxipam

Pyrazolam

Zolazepam

7-aminoclonazepam-𝑑4
(internal standard)

9.3

6.23

11

7.4

8.6

8

5.2

9

4.2

3.4

0.90

0.95

305

309.1

319

327

333

371

338

330.1

316.1

354

287.1

290

140

155

33

77.1

155

65

280.1

170

21

225.1

170

21

227

150

29

154

150

29

223

190

48

299

190

30

226.1

160

29

104.1

160

65

292.1

190

25

223

190

45

292

175

28

264

175

38

284.1

160

25

151

160

81

298

130

9

270

130

17

167

195

41

206

195

33

138.1

150

33

243.1

150

41

121

147

34

226

147

25

9
Chlordiazepoxide-𝑑5

2.5

305

(internal standard)
9.1

Diazepam-𝑑5

290

(internal standard)
Nordiazepam-𝑑5

6

276

(internal standard)
Temazepam-𝑑5

8.6

306

(internal standard)

286

115

23

232

115

41

198

155

36

154

165

29

213

160

30

139

160

46

260

125

25

198

145

40

2.5. Method Validation
The method was validated according to the Scientific Working Group for Forensic
Toxicology (SWGTOX) guidelines (Scientific Working Group for Forensic Toxicology, 2013),
so that the method can be applied to casework. The parameters analyzed were calibration model,
bias, intra and inter-day precision, limit of quantitation (LOQ)/ limit of detection (LOD), carry
over, interferences, matrix effects, dilution integrity, and stability.

2.5.1.

Calibration Curve Linearity

The calibration model was explored over a range of 1-500 ng/mL by fortifying drug-free
calf blood samples with the working solutions and IS (1 mg/L), extracting, and analyzing as
described above. The calibration curves were obtained by plotting the ratio of the peak area
of the analyte to that of the IS versus the concentration. The linear range of each compound
was determined by running all seven concentrations in five replications, in which each
replication was prepared fresh.
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2.5.2.

Limit of Detection (LOD) and Quantification (LOQ)

The LOD was considered to be the lowest concentration at which the analyte response
could be differentiated from that of background noise and had a signal-to-noise ratio (S/N)
≥3. The LOQ was the lowest calibrator concentration on the curve and was monitored by
analyzing nine replicate samples, three replicates over three separate days, for bias and
precision values (within-run and between-run) to be within 20%.

2.5.3.

Bias and Precision

Bias and precision were evaluated by analyzing the QC samples at 3, 40, 80, and 300
ng/mL in triplicate over the course of five different days. For each compound, three of the
four concentrations were chosen for low, medium, and high QC depending on the linear
range. The acceptable bias range was within ± 20% of each concentration. Precision was
assessed using the analysis of variance (ANOVA) approach for the coefficient of variance
(%CV) of within-run and between-run values, which should not exceed 20% for each QC
level.

2.5.4.

Matrix effect and extraction efficiency

To evaluate the matrix effect, three sets of samples (set 1, set 2, set 3) were prepared by
fortifying working solutions of the designer benzodiazepines and IS into thirteen sources of
negative blood distributed amongst the samples, which consisted of calf blood (1),
postmortem blood (11), and decomposed samples (1). Set 1 contained neat samples of low
QC (3 ng/mL) and high QC (300 ng/mL) prepared in five replicates. Set 2 consisted of five
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different sources of blood each fortified with both low and high QC and extracted as normal,
totaling to ten samples. Set 3 consisted of ten different sources of blood which were extracted
and then fortified with low and high QC after elution, totaling twenty samples. A comparison
of set 1 to set 3 was used to calculate matrix effects, a comparison of set 2 to set 3 was used
to demonstrate extraction efficiency. Ion suppression and enhancement were analyzed to
determine if each analyte in question is influenced by various matrices in the same manner to
ensure that quantification of that analyte is not affected, therefore the relative standard
deviation (%RSD) of matrix effect values should be within 20%.

2.5.5.

Carryover

Carryover studies were determined by injecting a negative sample after a sample with
concentrations at 200, 500, and 1000 ng/mL each in triplicate. Carryover is not present if the
negative samples do not exhibit a signal greater than that of the LOD.

2.5.6.

Interferences

Interference studies were conducted by fortifying a low QC (3 ng/mL) in triplicate with
other common drugs of abuse at high concentrations - methadone at 1,000 ng/mL,
amphetamines, other opioids, and common prescription benzodiazepines at 500 ng/mL, and
synthetic opioids at 100 ng/mL. If the QC sample calculates within 20% of the expected
value, then it can be said that the other drugs did not interfere with the analysis. Endogenous
interference studies were also performed by preparing samples in negative calf blood with
only internal standard and only analytes in triplicate.
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2.5.7.

Dilution Integrity

Dilution integrity was explored by performing a 1:2 dilution of a 200 ng/mL fortified
sample and a 1:5 dilution of a 500 ng/mL fortified sample both in calf blood. The original
samples were diluted in triplicate with blank blood, and the compounds must quantify within
20% of the target values when multiplied by their respective dilution factors.

2.5.8.

Stability

Stability of the analytes was experimented by re-injecting the QC samples after 24 and 48
h on the autosampler, which was kept at room temperature. Stability was evaluated by
comparing the percent difference of the concentration values of fresh samples versus the reinjected sample, which should stay within 20%.

2.6. Identification and Quantification Criteria
The identification criteria for the presence of an analyte was that the peak indicated for
the compound had a retention time ± 0.2 min window of the average retention times from the
calibrators, both the quantifier and qualifier ions were both present, and that the ion ratio was
within ± 20% of the average ion ratio of the calibrators. The quantification criteria for an analyte
is that the calibration curve must contain at least five of the seven points and that the 𝑅 2 ﹥0.99. In
addition, if points on the curve were disabled, then the QC samples within the linear range had to
quantitate within ± 20% of the expected value.
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2.7. Authentic Sample Analysis
The NYC-OCME toxicology department provided 33 postmortem blood samples
consisting of either femoral or heart blood, which were collected in blood bottles and vacutainer
glass collection tubes from 2016 to 2018 and stored in the freezer at -25°C. These specific
samples were chosen because during routine analysis, which consisted of an initial screening by
immunoassay and targeted analysis using GC-MS or LC-MS/MS, etizolam and delorazepam
were detected. Both of these compounds are non-traditional benzodiazepines and therefore could
potentiate use of other benzodiazepines and benzodiazepine analogs. Prior to analysis, the
samples were removed from the freezer and were left in the refrigerator at 4°C overnight to
defrost before aliquoting into 16 x 125 mm glass culture tubes for SPE extraction and LCMS/MS analysis under the conditions as described above.

3. Results
3.1. Chromatography
The LC-MS/MS method applied for the analysis of the panel of designer benzodiazepines
had excellent sensitivity and selectivity with the ability to detect all the compounds of interest
within the linear range of 1-500 ng/mL. The chromatographic separation, in which each
compound was able to be detected, is shown in the total ion chromatogram (TIC) of a low QC
sample at 3 ng/mL below in Figure 1.
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Figure 1. Total ion chromatogram (TIC) of a low QC sample at 3 ng/mL. The order of elution
shown in the TIC of all the analytes and internal standards was as follows: zolazepam, 7aminoclonazepam-𝑑4 , chlordiazepoxide-𝑑5 , pyrazolam, nifoxipam, flunitrazolam, clonazolam,
deschloroetizolam, nordiazepam-𝑑5 , flualprazolam, 3-hydroxyphenazepam, flubromazolam,
temazepam-𝑑5 , flubromazepam, meclonazepam, clobazam, delorazepam, diazepam-𝑑5 ,
diclazepam, and 4-chlorodiazepam. Note that the additional internal standards were included in
the working solution, but were not used for this method. See Appendix B for an extracted ion
chromatogram for each analyte.

3.2. Method Validation
The method was validated for the quantification of 13 of the 15 designer benzodiazepines
in blood from the panel. The 13 designer benzodiazepines consisted of 3-hydroxyphenazepam,
clobazam, clonazolam, delorazepam, deschloroetizolam, diclazepam, flualprazolam,
flubromazepam, flubromazolam, flunitrazolam, meclonazepam, nifoxipam, and pyrazolam. 4-
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chlorodiazepam and zolazepam were monitored for qualitative analysis only. The results for the
method validation are summarized in each section below.

3.2.1. Linearity
The internal standards used for each standard is shown in Table 3 based on the proximity
of the retention times. The calibration models were linear over a concentration range of 1200 ng/mL, except for 3-hydroxyphenazepam, clobazam, flubromazepam, and pyrazolam,
which had a concentration range of 1-500 ng/mL. All compounds had a line of best fit
following a linear regression with a 1/𝑥 2 weighting for all compounds, except 3hydroxyphenazepam and flubromazolam, which followed a 1/x weighting, and had an 𝑅 2 ﹥
0.99, which is shown in Table 4.

Table 3. Summary of the internal standards used for each compound and their retention times
Compound Name
Retention
Internal Standard
Retention
Time (min)
Time (min)
3-hydroxyphenazepam
7.9
8.6
Temazepam-𝑑5
4-chlorodiazepam

11.1

Diazepam-𝑑5

9.1

Clobazam

9.1

Diazepam-𝑑5

9.1

Clonazolam

6.3

Nordiazepam-𝑑5

6.0

Delorazepam

9.3

Diazepam-𝑑5

9.1

Deschloroetizolam

6.23

Nordiazepam-𝑑5

6.0

Diclazepam

11

Diazepam-𝑑5

9.1

Flualprazolam

7.4

Temazepam-𝑑5

8.6

Flubromazepam

8.6

Temazepam-𝑑5

8.6
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Flubromazolam

8

Temazepam-𝑑5

8.6

Flunitrazolam

5.2

Nordiazepam-𝑑5

6.0

Meclonazepam

9

Diazepam-𝑑5

9.1

Nifoxipam

4.2

Diazepam-𝑑5

9.1

Pyrazolam

3.4

Chlordiazepoxide-𝑑5

2.5

Zolazepam

0.90

7-aminoclonazepam-𝑑4

0.95

Table 4. Summary of the linearity ranges, weighting, average 𝑅 2 values, CV% of 𝑅 2 values,
average slope values, and CV% of the slope values of each compound (n = 15)
Compound Name

Linearity Weighting
Range
(ng/mL)

Average
𝑹𝟐 Value

CV% of
𝑹𝟐 Values

Average
Slope

CV% of
Slopes

3-hydroxyphenazepam

1-500

1/x

0.9986

0.098

0.1199

9.146

Clobazam

1-500

1/𝑥 2

0.9949

0.307

1.9193

11.342

Clonazolam

1-200

1/𝑥 2

0.9924

0.557

2.8223

18.298

Delorazepam

1-200

1/𝑥 2

0.9965

0.174

0.2961

5.553

Deschloroetizolam

1-200

1/𝑥 2

0.9962

0.303

6.5509

8.624

Diclazepam

1-200

1/𝑥 2

0.9957

0.211

0.2746

19.567

Flualprazolam

1-200

1/𝑥 2

0.9947

0.174

0.7196

15.615

Flubromazepam

1-500

1/𝑥 2

0.9962

0.178

0.1409

11.970

Flubromazolam

1-200

1/x

0.9971

0.198

0.3514

5.884

Flunitrazolam

1-200

1/𝑥

0.9978

0.209

5.0754

6.585

Meclonazepam

1-200

1/𝑥 2

0.9960

0.170

0.5974

8.043

Nifoxipam

1-200

1/𝑥 2

0.9935

0.203

0.0691

11.397

Pyrazolam

1-500

1/𝑥 2

0.9936

0.358

0.1010

8.334
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3.2.2. LOQ and LOD
The determined LOQ for all analytes was 1 ng/mL where the % bias of the compounds
were within ± 20% of the expected value. The intra- and inter-day imprecision % CV also
did not exceed 20% except for diclazepam and pyrazolam, which were slightly greater. The
results for bias and imprecision are summarized in Table 5 below. The predetermined LOD
criteria were met for 0.5 ng/mL where the samples run in triplicate had a signal to noise ratio
greater than 3.

Table 5. Summary of bias, intra- and inter-day precision results for the LOQ (1 ng/mL) of
each analyte (n = 9)
Compound Name

Bias (%)

Imprecision CV (%)
Intra-day

Inter-day

3-hydroxyphenazepam

-5.78

7.49

9.90

Clobazam

12.00

6.44

6.25

Clonazolam

7.78

14.70

12.33

Delorazepam

6.33

7.61

8.01

Deschloroetizolam

10.78

11.41

12.87

Diclazepam

8.89

20.87

21.74

Flualprazolam

14.22

10.70

9.75

Flubromazepam

-19.78

9.37

10.59

Flubromazolam

-2.67

11.92

15.98

Flunitrazolam

15.89

13.47

11.09

Meclonazepam

0.78

6.62

18.18

Nifoxipam

-0.11

8.04

15.03

Pyrazolam

2.78

21.99

21.61
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3.2.3. Bias and Precision
The accuracy of the 15 replicates of all compounds were monitored at the low QC (3
ng/mL), mid QC (40 ng/mL), and high QC (80 ng/mL), except for 3-hydroxyphenazepam,
clobazam, and flubromazepam, which have a mid QC at 80 ng/mL and high QC at 300
ng/mL due to their expanded calibration ranges. The calculated mean and bias results were
within acceptable ranges of ± 15% the expected value as shown in Table 6 below.
Table 6. Summary of bias results for low, mid, and high QC for each compound (n = 15)
Compound Name

3-hydroxyphenazepam
QC = 3, 80, 300 ng/mL
Clobazam
QC = 3, 80, 300 ng/mL
Clonazolam
QC = 3, 40, 80 ng/mL
Delorazepam
QC = 3, 40, 80 ng/mL
Deschloroetizolam
QC = 3, 40, 80 ng/mL
Diclazepam
QC = 3, 40, 80 ng/mL
Flualprazolam
QC = 3, 40, 80 ng/mL
Flubromazepam
QC = 3, 80, 300 ng/mL
Flubromazolam
QC = 3, 40, 80 ng/mL
Flunitrazolam
QC = 3, 40, 80 ng/mL
Meclonazepam
QC = 3, 40, 80 ng/mL
Nifoxipam
QC = 3, 40, 80 ng/mL
Pyrazolam
QC = 3, 40, 80 ng/mL

Bias (%)
Low QC

Mid QC

High QC

-9.58

-7.03

-0.82

-11.76

-6.40

3.64

11.60

10.34

-0.76

7.22

8.51

5.76

1.13

4.92

2.47

4.02

2.81

-5.83

2.71

1.38

-5.40

-10.64

-10.53

-7.95

-3.02

1.11

-4.02

1.20

2.99

3.53

3.64

5.29

2.06

-6.58

1.81

3.60

-7.78

-8.02

-9.57
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All intra-day imprecision CV results were within 20% as shown below in Table 7 and all
inter-day imprecision CV results were within 20%, except for diclazepam at mid QC, which
was slightly above.

Table 7. Summary of intra- and inter-day precision results at low, mid, and high QC for each
compound (n = 15)
Compound Name

Low QC
Mid QC
High QC
Imprecision CV (%) Imprecision CV (%) Imprecision CV (%)

Intra-day
3-hydroxyphenazepam
QC = 3, 80, 300 ng/mL
Clobazam
QC = 3, 80, 300 ng/mL
Clonazolam
QC = 3, 40, 80 ng/mL
Delorazepam
QC = 3, 40, 80 ng/mL
Deschloroetizolam
QC = 3, 40, 80 ng/mL
Diclazepam
QC = 3, 40, 80 ng/mL
Flualprazolam
QC = 3, 40, 80 ng/mL
Flubromazepam
QC = 3, 80, 300 ng/mL
Flubromazolam
QC = 3, 40, 80 ng/mL
Flunitrazolam
QC = 3, 40, 80 ng/mL
Meclonazepam
QC = 3, 40, 80 ng/mL
Nifoxipam
QC = 3, 40, 80 ng/mL
Pyrazolam
QC = 3, 40, 80 ng/mL

Inter-day Intra-day

Inter-day Intra-day Inter-day

4.70

4.67

5.95

8.31

5.14

6.99

3.68

5.06

7.74

7.93

5.27

7.12

6.02

8.88

7.37

11.43

4.65

6.44

3.77

4.99

6.03

6.36

5.48

6.30

7.26

9.82

8.06

12.29

5.66

8.17

12.24

13.38

19.11

20.58

8.92

11.97

15.41

16.16

9.03

8.68

9.10

10.04

7.16

11.35

8.15

8.92

12.99

12.47

9.06

10.16

10.73

9.88

8.37

8.331

6.07

8.64

8.81

10.39

6.39

7.55

4.95

6.15

5.41

6.97

6.89

7.09

6.27

7.54

6.46

7.21

6.67

6.25

12.70

13.90

7.73

8.47

10.30

11.36
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3.2.4. Matrix effect and extraction efficiency
Matrix effect will cause either ion suppression, seen as negative values, or enhancement,
which is seen as positive values. It can be said that a compound is not significantly
susceptible to matrix effect if the value is within ± 25% of the expected value. Should an
analyte have significant matrix effect, then it has to be proven that the matrix effect does not
inhibit the analysis. Matrix effect is within the ± 25% acceptable range for all compounds,
except delorazepam at high concentrations, deschloroetizolam at low concentrations,
diclazepam at both high and low concentrations, and flubromazepam at low concentrations,
as shown in Table 8. It is shown that %RSD is within 20% indicating that the analyte exhibits
the same behavior in each matrix and is repeatable for testing conditions, so matrix effect is
not a concern in the quantification of the analytes.

Table 8. Summary of matrix effect results for each compound at low QC (3 ng/mL) and high QC
(300 ng/mL) in blood samples (n = 10)
Compound Name
Low QC 3 ng/mL
High QC 300 ng/mL
Matrix Effect (%)
3-hydroxyphenazepam

Matrix Effect
(%)

RSD (%)

RSD (%)

2.1

5.2

3.3

4.6

-79.4

22.7

-66.9

19.0

17.4

19.8

0.9

4.7

Clonazolam

-10.5

4.9

13.6

4.3

Delorazepam

-5.2

7.7

-52.1

4.8

Deschloroetizolam

-29.6

11.4

-12.1

3.2

Diclazepam

-41.9

17.3

-39.5

16.4

7.8

17.0

4.2

8.0

32.4

8.0

10.4

7.5

4-chlorodiazepam
Clobazam

Flualprazolam
Flubromazepam
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Flubromazolam

-1.8

12.9

1.8

7.3

Flunitrazolam

-3.0

8.0

-1.9

4.4

Meclonazepam

-7.9

6.7

-5.8

3.9

Nifoxipam

8.9

9.5

2.0

8.5

Pyrazolam

-15.6

9.5

-4.9

7.1

Zolazepam

-33.8

11.7

-21.2

6.6

5.4

3.4

-14.4

12.2

-12.2

5.1

-6.7

4.2

-8.5

4.6

-7.5

3.2

Nordiazepam-𝑑5

2.2

6.5

-5.0

3.8

Temazepam-𝑑5

-6.0

4.5

-0.1

5.5

7-aminoclonazepam-𝑑4
Chlordiazepoxide-𝑑5
Diazepam-𝑑5

Extraction efficiency was evaluated for all the compounds, which ranged from 35.483.9%. Nifoxipam had low recovery at 37.3% for low QC (3 ng/mL) and 35.4% for high QC
(300 ng/mL) and 3-hydroxyphenazepam also had a slightly low recovery at 49.6% at low QC
and 49.0% at high QC, but all other compounds had extraction efficiencies greater than 50%,
which is the optimal extraction efficiency. Despite the values below the optimal extraction
efficiency, the other validation parameters were not affected and met the acceptability
criteria, so it can be said that the low extraction efficiency did not compromise the analysis.

3.2.5. Carryover
Carryover was not present in any of the blank matrix samples injected after the
concentrations of 200, 500, and 1,000 ng/mL in triplicate. None of the blank matrix samples
displayed a signal to noise ratio greater than that of the LOD.
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3.2.6. Interferences
The present studies showed that endogenous compounds did not cause interference in
specificity and selectivity of the analysis. The identification of the target analytes was not
influenced by exogenous compounds; however, there was potential interference for the
quantitation of delorazepam, diclazepam, flubromazepam, flunitrazolam, and pyrazolam.
Delorazepam, diclazepam, and pyrazolam had accuracies greater than 120% and
flubromazepam and flunitrazolam had accuracies less than 80% of the low QC (3 ng/mL). It
is uncertain as to the source of interference for delorazepam and diclazepam, but additional
studies will be performed to confirm as to which of the commonly abused drugs are causing
the interference. All other compounds quantitated within ± 20% of the low QC.

3.2.7. Dilution Integrity
Drug-free calf blood was used to test a 1:2 dilution of a prepared 200 ng/mL sample and
a 1:5 dilution of a 500 ng/mL sample with both concentrations analyzed in triplicate. The
concentrations of the repeats for diclazepam in the 1:5 dilution and nifoxipam in the
1:2 dilution did not quantitate within 20% of the expected concentration. Diclazepam
quantitated -40.2% of the expected value and nifoxipam quantitated 52.5% above the
expected value. The other analytes calculated within the ± 20% range for one or more repeat
for both the 1:2 and 1:5 dilution.

3.2.8. Stability
Extracted samples at low and high QC were re-injected after 24 and 48 h on the
autosampler, which was kept at room temperature to test for analyte stability. Nifoxipam
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showed deterioration at high QC of -25.7% and flubromazepam at low and high QC of 56.6% and -52.5%, respectively, after 24 h. Clonazolam, deschloroetizolam, diclazepam,
flualprazolam, and flunitrazolam had a percent difference either at or greater than 25% after
24 h compared to the original sample. Clonazolam at low and high QC had a difference of
55.6% and 72.4%, respectively. Deschloroetizolam at low and high QC had a difference of
55.1% and 57.4%, respectively. Diclazepam had a difference of 66.1% at low QC and 31.8%
at high QC. Flualprazolam had a difference of 25% at low QC after 24 h and a difference of
36.4% at high QC after 48 h. Flunitrazolam at low and high QC had a difference of 51.7%
and 50.1%, respectively. 3-hydroxyphenazepam at low and high QC and flubromazolam at
high QC had a percent difference exceeding 25% after 48 h on the autosampler, which were
32.4%, 34.5%, and 29.4%, respectively. All other analytes had results within the acceptable
range between fresh samples and samples on the autosampler after the allotted time.

3.3. Authentic Case Samples
Postmortem blood samples were subjected to the conditions of the aforementioned
method. Of the thirty-three samples that were re-analyzed, five of the samples tested positive for
additional designer benzodiazepines, including clonazolam, delorazepam, diclazepam,
flualprazolam, and flubromazolam. The drugs found along with their concentrations in each case,
and the original test results are summarized in Table 9 and a comparison of the peak signal of
clonazolam in authentic case 4 to that at the LOQ (1 ng/mL) is shown below in Figure 2.
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Table 9. Additional Designer Benzodiazepines Identified in Postmortem Blood Samples
Originally Tested between 2016 to 2018
Case and Source Original Test Results
Additional Drugs Identified
1 (Heart)

Lorazepam – 13 ng/mL (GC-MS)

Delorazepam – 68.91 ng/mL

Etizolam – detected (GC-MS)

Diclazepam – 0.93 ng/mL
Flubromazolam – 40.37 ng/mL

2 (Femoral)

Etizolam – detected (GC-MS)

Delorazepam – 1.13 ng/mL

3 (Femoral)

Diazepam – 458 ng/mL (LC-MS/MS)

Delorazepam – 68.69 ng/mL

Nordiazepam – 1,106 ng/mL (LCMS/MS)
Etizolam – 56 ng/mL (LC-MS/MS)
Lorazepam – 12 ng/mL (LC-MS/MS)
Oxazepam – 29 ng/mL (LC-MS/MS)
Temazepam – 38 ng/mL (LC-MS/MS)
4 (Femoral)

7-aminoclonazepam – 1.3 ng/mL (LCMS/MS)

Clonazolam – 1.16 ng/mL

Etizolam – 15 ng/mL (LC-MS/MS)
5 (Femoral)

Alprazolam – 171 ng/mL (LC-MS/MS)

Delorazepam – 5.38 ng/mL

Alphahydroxyalprazolam – 5.1 ng/mL
(LC-MS/MS)

Flualprazolam – 1.94 ng/mL

Lorazepam – 1.4 ng/mL (LC-MS/MS)
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Figure 2. Comparison of peak signal and ion ratios of clonazolam in authentic case 4 (top) to the
LOQ at 1 ng/mL (bottom)

4. Discussion
The quantification method for designer benzodiazepines in blood was validated for 13 of
the 15 compounds, while 4-chlorodiazepam and zolazepam were monitored for qualitative
analysis only. All method validation criteria was explored and tested to see if the necessary
standards were met. The LOQ was set at 1 ng/mL and the LOD was 0.5 ng/mL (S/N >3). Bias
and precision CV% quantitated within the required 20% with the exception of diclazepam at mid
QC (40 ng/mL) for inter-day imprecision, which was just barely above. Although there was
matrix effect and low extraction efficiencies for a few of the compounds, the other method
validation parameters were not affected and is not considered a concern for the quantification of
the 13 analytes. Carryover was not present in samples as high as 1,000 ng/mL as seen in the
blank injections performed in triplicate. Compounds quantitated within the range of 20% the
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expected concentration with the exception of diclazepam in the 1:5 dilution and nifoxipam in the
1:2 dilution.
There were some issues regarding interference studies and stability of the compounds. It
was observed that there were no endogenous interferences and that the majority of the target
analytes were not affected by exogenous compounds. However, it has been reported that
chlordiazepoxide and midazolam interfere with flubromazepam analysis, while oxazepam
interferes with pyrazolam (NMS Labs, 2018). Because flunitrazolam shares a highly similar
structure to flubromazepam, chlordiazepoxide and midazolam are also potential interferences to
this compound.
There is limited published data regarding the stability of designer benzodiazepines, but
the drugs share similar properties with classic benzodiazepines, since the designer drugs are
derivatives of the 1, 4-benzodiazepine structure. Previous studies show that benzodiazepines in
general are not stable with a few exceptions, such as diazepam. A compound is also said to be
more stable if it is a metabolite, rather than a parent compound (Uddin, Samanidou, &
Papadoyannis, 2010; Dixon, Mbeunkui, & Wiegel, 2015; Gautam, Sharratt, & Cole, 2014).
Benzodiazepines are more unstable if stored in positive temperatures, which was tested in a
study where benzodiazepines stored at room temperatures were extracted and analyzed after set
amounts of time. After a year, the quantitated value of the low concentration samples decreased
by 100% (Gautam, Sharratt, & Cole, 2014; Mahjoub & Staub, 2000). Another study tested the
stability of post extracted benzodiazepines in hair by storing the samples in the autosampler at
10˚C, showing degradation in some analytes after 48 h up to 54.8% loss (Lendoiro et al., 2012).
Compared to other methods described, this method simultaneously quantitates 13
designer benzodiazepines in 0.5 mL of blood through the use of SPE cleanup followed by a 13.5
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min run time and LC-MS/MS analysis. The LOQ of all the compounds was as low as 1 ng/mL.
Previous publications have focused on urine as the biological matrix. An ultrasound-assisted
low-density solvent dispersive liquid-liquid microextraction was employed to determine 4
designer benzodiazepines in 1 mL of urine using GC-MS/MS that had a total run time of 20 min
and a linear range of 0.3 to 20,000 ng/mL (Meng et al., 2017). Another method analyzed 11
designer benzodiazepines in urine using LC-MS/MS by direct injection after enzymatic
hydrolysis (Bergstrand et al., 2016). In this method 50 µL of urine were employed, achieving an
LOQ from 1 to 10 ng/mL.
Two other publications reported analytical methods for the determination of a limited
number of designer benzodiazepines in blood. One discussed the analysis of etizolam and its two
metabolites in 1 mL of whole blood by using SPE cleanup with a derivatization step and analysis
using ion trap GC-MS over a 17 min run time with a linear range of 5-50 ng/mL (Nakamae et al.,
2008). Hoiseth et al. briefly described a quantitation method for 6 designer benzodiazepines
using liquid-liquid extraction (borate buffer pH 11 and ethyl acetate/heptane, 4:1) followed by
LC-MS/MS analysis. They achieved LOQs from 0.37 to 3.5 ng/mL, but the required amount of
blood was not reported (Hoiseth et al., 2016). In comparison to previously published methods,
the validated method is an alternative for a simultaneous determination of 13 designer
benzodiazepines using a quick and easy sample preparation that requires a small volume of blood
sample (0.5 mL), a fast run time on the LC-MS/MS, which is specific and sensitive, and has a
LOQ as low as 1 ng/mL. In addition, this developed method has been combined with the current
in-house method for routine testing to monitor a total of 35 benzodiazepine drugs and
metabolites.
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5. Conclusion
A reproducible, simple, and specific method was validated for the simultaneous
determination of 13 designer benzodiazepines in blood. This method utilized a SPE procedure
and a 13.5 min run time on the LC-MS/MS. Even with the increase in usage of designer
benzodiazepines as monitored over the last several years, there have been a limited number
involving LC-MS/MS techniques described in literature. This method provides an alternative
technique in contrast to those that use urine as the matrix or GC-MS as the instrument of
analysis.

6. Future Work
With the implementation for the quantitation method of designer benzodiazepines on the
LC-MS/MS, the next step will be the development of a sensitive screening technique by liquid
chromatography-time of flight mass spectrometer (LC-TOF/MS). Currently being tested is a
quick dilute-and-shoot method of sample clean-up for a mixture of 35 benzodiazepines and
designer benzodiazepines and 10 internal standards in blood. The identification criteria in the
LC-TOF/MS consists on retention time and precursor accurate mass.
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8. Appendix
Appendix A: Acronyms and Abbreviations
AJS-ESI

Agilent Jet Stream - Electrospray Ionization

ANOVA

Analysis of Variance

CV

Coefficient of Variation

GC-MS

Gas Chromatography-Mass Spectrometry

GC-MS/MS

Gas Chromatography-Tandem Mass Spectrometry

IS

Internal Standard

LC-MS/MS

Liquid Chromatography-Mass Spectrometry

LC-QTOF/MS

Liquid Chromatography Quadrupole Time-of-Flight Mass Spectrometry

LC-TOF/MS

Liquid Chromatography Time-of-Flight Mass Spectrometry

LLE

Liquid-liquid Extraction

LOD

Limit of Detection

LOQ

Limit of Quantitation

MRM

Multiple Reaction Monitoring

MS

Mass Spectrometry

NPS

New Psychoactive Substances

NYC-OCME

New York City Office of Chief Medical Examiner

QC

Quality Control

RSD

Relative Standard Deviation

S/N

Signal to Noise

SOP

Standard Operating Procedure

SPE

Solid Phase Extraction
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SWGTOX

Scientific Group for Forensic Toxicology

TIC

Total Ion Chromatogram

Appendix B: Extracted ion chromatograms of each analyte at 3 ng/mL
3-hydroxyphenazepam

4-chlorodiazepam

Clobazam
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Clonazolam

Delorazepam

Deschloroetizolam

Diclazepam

36
Flualprazolam

Flubromazepam

Flubromazolam

Flunitrazolam

37
Meclonazepam

Nifoxipam

Pyrazolam

Zolazepam

38
7-aminoclonazepam-𝑑4

Chlordiazepoxide-𝑑5

Diazepam-𝑑5

Nordiazepam-𝑑5

39
Temazepam-𝑑5

Figure 3. Extracted ion chromatograms of each analyte at 3 ng/mL. The quantifier transition is
shown in the peak on the left and the qualifier transition is shown on the right.

